期刊文献+

恶性胶质瘤术后采用替莫唑胺同期放疗、化疗临床观察 被引量:1

下载PDF
导出
摘要 目的探讨恶性胶质瘤手术后应用替莫唑胺同期放疗、化疗的疗效和不良反应。方法2002年10月-2006年6月,对19恶性胶质瘤术后患者,采用替莫唑胺同期放疗、化疗(TMZ组)。化疗在放疗的第1天开始,替莫唑胺剂量每天100 mg/m^2,d1-5,每28天重复;放疗采用局部野常规照射(肿瘤量58-62 Gy/29-31次)。并选择36例恶性胶质瘤患者术后采用司莫司汀同期放疗、化疗的患者(Me-CCNU组)进行对照。结果TMZ组1、2年生存率分别为52.6%、26.3%;Me-CCNU组1、2年生存率分别为41.7%、19.4%;中位生存期TMZ组为14.1个月,Me-CCNU组为11.2月(P=0.036)。和度骨髓抑制,TMZ组为15.7%,Me-CCNU组为16.7%(P〉0.05)。结论恶性胶质瘤患者术后应用TMZ同期放疗、化疗疗效好,安全性高,患者能耐受。
出处 《实用肿瘤杂志》 CAS 2007年第5期440-442,共3页 Journal of Practical Oncology
  • 相关文献

参考文献12

  • 1Sehgal A.Molecular changes during the genesis of human gliomas[J].Semin Surg Oncol,1998,14(1):3-12.
  • 2Kortmann RD,Jeremic B,Weller M,et al.Radiochemotherapy of malignant glioma in adults[J].Strahlenther Oncol,2003,179(4):219-232.
  • 3Kristiansen K,Hagen S,Kollevold T,et al.Combined modality therapy of operated astrocytomas grade Ⅲ and Ⅳ.Confirmation of the value of post-operative irradiation and lack of potentiation of bleomycin on survival time[J].Cancer,1981,47(4):649-652.
  • 4左焕琮,王世杰,赵奎明,唐文渊,马廉亭.恶性胶质瘤同步放射化学治疗继以动脉灌注嘧啶亚硝脲治疗观察[J].中华神经外科杂志,1996,12(4):201-204. 被引量:20
  • 5Stupp R,Gander M,Leyvraz S,et al.Current and future developments in the use of temozolomide for the treatment of brain tumours[J].Lancet Oncol,2001,2(9):552-560.
  • 6Van Rijn J,Heimans JJ,van den Berg J,et al.Survival of human glioma cells treated with various combination of temozolomide and X-rays[J].Int J Radiat Oncol Biol Phys,2000,47(3):779-784.
  • 7Ostermann S,Csajka C,Buclin T,et al.Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients[J].Clin Cancer Res,2004,10(11):3728-3736.
  • 8Stupp R,Mason WP,van den Bent MJ,et al.Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma[J].N Engl J Med,2005,352(10):987-996.
  • 9Athanassiou H,Synodinou M,Maragoudakis E,et al.Randomized phase Ⅱ study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme[J].J Clin Oncol,2005,23(10):2372-2377.
  • 10Prados MD,Wara WM,Sneed PK,et al.Phase Ⅲ trial of accelerated hyperfractionation with or without difluromethylonithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme[J].Int J Radiat Oncol Biol Phys,2001,49(1):71-77.

共引文献19

同被引文献6

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部